Tag: Xtandi for nmCSPC

Home / Xtandi for nmCSPC

Categories

Enzalutamide is approved by the USFDA for non-metastatic castration-sensitive prostate cancer with biochemical recurrence

The FDA has authorized enzalutamide for the treatment of non-metastatic castration-sensitive prostate cancer in cases of biochemical recurrence.The Food and Drug Administration approved enzalutamide ...
xtandi-for-nmcspc

Scan the code